UY33453A - Método para el tratamiento de la hipertensión pulmonar mediante el uso de ranozalina - Google Patents

Método para el tratamiento de la hipertensión pulmonar mediante el uso de ranozalina

Info

Publication number
UY33453A
UY33453A UY0001033453A UY33453A UY33453A UY 33453 A UY33453 A UY 33453A UY 0001033453 A UY0001033453 A UY 0001033453A UY 33453 A UY33453 A UY 33453A UY 33453 A UY33453 A UY 33453A
Authority
UY
Uruguay
Prior art keywords
ranozaline
treatment
pulmonary hypertension
pulmonary
hypertension
Prior art date
Application number
UY0001033453A
Other languages
English (en)
Inventor
Belardinelli Luiz
Original Assignee
Gilead Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gilead Sciences Inc filed Critical Gilead Sciences Inc
Publication of UY33453A publication Critical patent/UY33453A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente divulgación se refiere en general al tratamiento de pacientes que padecen hipertensión pulmonar, tal como hipertensión arterial pulmonar (HAP), o síntomas asociados con dicha enfermedad, administrando una cantidad terapéuticamente eficaz de ranozalina o una sal o sales de la misma al paciente.
UY0001033453A 2010-06-16 2011-06-14 Método para el tratamiento de la hipertensión pulmonar mediante el uso de ranozalina UY33453A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US35546210P 2010-06-16 2010-06-16
US40786410P 2010-10-28 2010-10-28

Publications (1)

Publication Number Publication Date
UY33453A true UY33453A (es) 2012-01-31

Family

ID=44202215

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001033453A UY33453A (es) 2010-06-16 2011-06-14 Método para el tratamiento de la hipertensión pulmonar mediante el uso de ranozalina

Country Status (9)

Country Link
US (1) US20120004188A1 (es)
EP (1) EP2582372A1 (es)
JP (1) JP2013528649A (es)
AR (1) AR081925A1 (es)
AU (1) AU2011267871A1 (es)
CA (1) CA2801707A1 (es)
TW (1) TW201215392A (es)
UY (1) UY33453A (es)
WO (1) WO2011159706A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2486712C (en) 2002-05-21 2012-01-03 Cv Therapeutics, Inc. Method of treating diabetes
US20130245469A1 (en) * 2012-03-19 2013-09-19 Cardiomems, Inc. Pulmonary Arterial Hemodynamic Monitoring for Chronic Obstructive Pulmonary Disease Assessment and Treatment
AU2013334081B2 (en) 2012-10-26 2017-05-18 Chiesi Farmaceutici S.P.A. Methods for controlling blood pressure and reducing dyspnea in heart failure
WO2014081958A1 (en) 2012-11-21 2014-05-30 Cardiomems, Inc. Devices, systems, and methods for pulmonary arterial hypertension (pah) assessment and treatment
WO2014145712A1 (en) 2013-03-15 2014-09-18 Cardiomems, Inc. Methods for the treatment of cardiovascular conditions
KR20190005708A (ko) * 2017-07-05 2019-01-16 이화여자대학교 산학협력단 에피디티오디옥소피페라진 화합물 또는 이의 유도체, 또는 이들의 약학적으로 허용가능한 염을 포함하는 폐동맥고혈압 예방 또는 치료용 약학적 조성물

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US4326525A (en) 1980-10-14 1982-04-27 Alza Corporation Osmotic device that improves delivery properties of agent in situ
US4567264A (en) 1983-05-18 1986-01-28 Syntex (U.S.A.) Inc. Cardioselective aryloxy- and arylthio- hydroxypropylene-piperazinyl acetanilides which affect calcium entry
US5364620A (en) 1983-12-22 1994-11-15 Elan Corporation, Plc Controlled absorption diltiazem formulation for once daily administration
US4902514A (en) 1988-07-21 1990-02-20 Alza Corporation Dosage form for administering nilvadipine for treating cardiovascular symptoms
US5455045A (en) 1993-05-13 1995-10-03 Syntex (U.S.A.) Inc. High dose formulations
US6303607B1 (en) 1998-09-10 2001-10-16 Cv Therapeutics, Inc. Method for administering a sustained release ranolanolazine formulation
KR20070093988A (ko) 2005-01-06 2007-09-19 씨브이 쎄러퓨틱스, 인코포레이티드 라놀라진 함유 서방성 약제학적 제형물
US20100010024A1 (en) * 2006-07-01 2010-01-14 Bayer Healthcare Ag Use of1,4-diaryl-dihydropyrimidine-2-on derivatives for treating pulmonary arterial hypertension
US20100130436A1 (en) 2008-11-25 2010-05-27 Gilead Palo Alto, Inc. Co-administration of ranolazine and cardiac glycosides

Also Published As

Publication number Publication date
JP2013528649A (ja) 2013-07-11
US20120004188A1 (en) 2012-01-05
TW201215392A (en) 2012-04-16
EP2582372A1 (en) 2013-04-24
AU2011267871A1 (en) 2013-01-10
CA2801707A1 (en) 2011-12-22
AR081925A1 (es) 2012-10-31
WO2011159706A1 (en) 2011-12-22

Similar Documents

Publication Publication Date Title
BR112014003225A2 (pt) profármacos de treprostinil ligados a veículo
CR11510A (es) Uso de un inhibidor de la gamma-secretasa para tratamiento del cancer
CO6480979A2 (es) Inhibidores de bace
UY33453A (es) Método para el tratamiento de la hipertensión pulmonar mediante el uso de ranozalina
NI201400083A (es) Compuesto de imidazopirrolidinona
AR065392A1 (es) Metodos para el tratamiento por inhalacion de una enfermedad o estado respiratorio
CL2013001602A1 (es) Metodo para reducir o inhibir la progresion del nivel de fatiga en pacientes con esclerosis multiple y para proporcionarles neuroproteccion que comprende administrar oralmente laquinimod o una sal del mismo; laquinimod para reducir el nivel de fatiga, mejorar el estado funcional y entregar neuroproteccion en esclerosis multiple.
BR112014003198A2 (pt) compostos para o tratamento e profilaxia de doença por vírus sincicial respiratório
MX356728B (es) Combinación farmacéutica para usar en el tratamiento de pacientes que padecen diabetes de tipo 2.
CL2013002593A1 (es) Forma cristalina a1 de la sal clorhidrato del compuesto 3-(5-amino-2-metil-4-oxo-4h-quinazolin-3-il)-piperidin-2,6-diona; composicion farmaceutica que la comprende; y su uso para tratar o prevenir una enfermedad o trastorno tal como cancer, angiogenesis, dolor, trastorno pulmonar y un trastorno del snc.
ECSP15008695A (es) Combinaciones farmacéuticas que comprenden un inhibidor de b-raf, un inhibidor de egfr y opcionalmente un inhibidor de pi3k-alfa
EA201500552A1 (ru) Лечение релаксином одышки, ассоциированной с острой сердечной недостаточностью
AU2012205878A8 (en) miRNA for treating diseases and conditions associated with neo-angiogenesis
CY1120094T1 (el) Φαρμακευτικη συνθεση που περιλαμβανει despr036 eξenδinh-4(1-39)-lys6-nh2 για χρηση στην θεραπευτικη αγωγη μιας νευροεκφυλιστικης ασθενειας
GT201200164A (es) "nuevos compuestos de espiropiperidina"
EP2582682A4 (en) METHOD FOR THE TREATMENT OF LUNG DISEASES
BR112012033738A2 (pt) método para o tratamento de transtorno bipolar
CO6592101A2 (es) Metodos para tratar ulceras de pie de diabetico
CO7160080A2 (es) Composiciones lipídicas de racecadotrillo
BR112012015984A2 (pt) composição para melhorar a função cerebral, e, polipeptídeo
NI201000173A (es) Uso de dronedarona o una sal aceptable farmacéuticamente de ésta, para la preparación de un medicamento para regular el nivel de potasio en la sangre.
AR090129A1 (es) Oligonucleotidos para la modulacion de la expresion genica y sus usos
EA201390616A1 (ru) ЛЕЧЕНИЕ НАРУШЕНИЙ, АССОЦИИРОВАННЫХ С ГЕНОМ MeCP2
BR112014008783A2 (pt) compostos para o tratamento e profilaxia da doença causada por vírus sincicial respiratório
ES2673406T3 (es) Alfa-derivados de ácidos grasos cis-monoinsaturados para uso como medicamentos en el tratamiento de la diabetes

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20200807